Business
Admission to Main Market, First Day of Dealings
Admission to Main Market, First Day of Dealings.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5755X\n Graft Polymer (UK) PLC\n 06 January 2022\n \n \n \n \n NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND DEPENDENCIES, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) (COLLECTIVELY, THE \"UNITED STATES\"), CANADA, AUSTRALIA, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW\n \n \n 6 January 2022\n \n \n Graft Polymer (UK) Plc\n \n \n (\"Graft Polymer\", the \"Company\", and together with its subsidiaries, the \"Group\")\n \n \n Admission to Main Market, First Day of Dealings\n \n \n Graft Polymer (UK) Plc (LSE: GPL), a business focused on the development of polymer modification, bio/food supplements and drug delivery systems, is pleased to announce the admission of its entire issued ordinary share capital to trading on the Main Market of the London Stock Exchange. Admission will take place and dealings will commence at 8.00 a.m. today under the ticker GPL. The Company's Admission Document is available to view on the Company's website at\n \n www.graftpolymer.com\n \n .\n \n \n \n Established in 2017 by a group of polymer technology experts and venture capitalists, Graft Polymer's core business comprises polymer modification and development of drug delivery systems. The Group is a highly innovative business with strong intellectual property holding several patent applications. The fundraising of £5 million is to fund accelerated growth, expand the Group's research and production facility in Slovenia to meet rising customer demand, upgrade existing facilities to enable future IP registration, and increase both inventory and marketing opportunities following expected increased sales.\n \n \n Key highlights:\n \n \n · \n Based on the Placing Price of 21.5p, the market capitalisation of the Company will be approximately £22.4m at Admission.\n \n \n · \n Placing raised approximately £5 million gross to fund expansion of research and production facility, upgrade existing laboratories, accelerate growth and increase both inventory and marketing abilities.\n \n \n ·\n The Company's ISIN is GB00BMD1Z199 and its SEDOL is \n BMD1Z19.\n \n \n ·\n Turner ...